Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Drug Resistance to BRAF Inhibitor.

Bulletin of mathematical biology - 14 Jan 2020

Friedman Avner, Siewe Nourridine

Abstract excerpt

One of the most frequently found mutations in human melanomas is in the B-raf gene, making its protein BRAF a key target for therapy. However, in patients treated with BRAF inhibitor (BRAFi), although the response is very good at first, relapse occurs within 6 months, on the average. In order to overcome this drug resistance to BRAFi, various combinations of BRAFi with other drugs have been explored, and some are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine CCL2
Share to Drug Resistance, Neoplasm
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mathematical Concepts

Share to Melanoma

Share to Melanoma, Experimental

Share to Programmed Cell Death 1 Receptor

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 31933021
DOI: 10.1007/s11538-019-00691-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Drug Resistance to BRAF Inhibitor.PMID 31933021Read ↗

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical modelSemantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanomaSemantic proximity Read ↗

[Mechanisms of resistance to anti-BRAF treatments].Semantic proximity Read ↗

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Semantic proximity Read ↗

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.Semantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

[BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].Semantic proximity Read ↗

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.Semantic proximity Read ↗

Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.Semantic proximity Read ↗

BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future ProspectsSemantic proximity Read ↗

BRAF mutation and its inhibitors in sarcoma treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.